/ATHA
ATHA Stock - Athira Pharma, Inc.
Healthcare|BiotechnologyNASDAQ
$6.97+3.72%
+$0.25 (+3.72%) • Dec 19
35
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.2
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-42.6%upside
Target: $4.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ATHA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.90 – $7.04
TARGET (TP)$4.00
STOP LOSS$6.41
RISK/REWARD1:-5.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.96
52W High$8.36
52W Low$2.20
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | $-479,000 | $-2,000,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-100,902,000 | $-125,466,000 | $-104,016,000 | $-64,022,000 | $-19,995,000 |
| Net Income | $-96,940,000 | $-117,672,000 | $-95,639,000 | $-54,853,000 | $-19,955,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-25.20 | $-30.90 | $-25.30 | $-14.90 | $-6.10 |
Company Overview
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
50%
Hold / Neutral
5
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
5 Bullish5 Neutral/Bearish
Price Targets
$15
Average Target
↑ 119.7% Upside
Now
$1
Low
$15
Average
$33
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 19th 2024 | Mizuho | Downgrade | Neutral | $0.5← $5 |
| September 4th 2024 | Rodman & Renshaw | Downgrade | Neutral | - |
| September 4th 2024 | BTIG Research | Downgrade | Neutral | - |
| September 4th 2024 | JMP Securities | Downgrade | Market Perform | - |
| August 19th 2024 | Rodman & Renshaw | Initiation | Buy | $22 |
| October 17th 2022 | JMP Securities | Upgrade | Mkt Outperform | $20 |
| July 7th 2022 | Mizuho | Initiation | Buy | $6 |
| June 23rd 2022 | Stifel | Downgrade | Hold | $5← $36 |
| June 23rd 2022 | JMP Securities | Downgrade | Market Perform | - |
| June 23rd 2022 | Jefferies | Downgrade | Hold | $3← $32 |
| May 10th 2022 | BTIG Research | Initiation | Buy | $33 |
| April 21st 2022 | Berenberg | Initiation | Buy | $33 |
Earnings History & Surprises
ATHABeat Rate
56%
Last 18 quarters
Avg Surprise
-1.3%
EPS vs Estimate
Beats / Misses
10/6
2 met exactly
Latest EPS
$-1.68
Q4 2025
EPS Surprise History
Q1 24
+26.0%
$-0.71vs$-0.96
Q2 24
+13.8%
$-0.69vs$-0.80
Q3 24
+6.7%
$-0.70vs$-0.75
Q4 24
+6.3%
$-0.75vs$-0.80
Q1 25
-69.6%
$-0.39vs$-0.23
Q2 25
-15.0%
$-0.23vs$-0.20
Q3 25
0.0%
$-1.80vs$-1.80
Q4 25
-58.5%
$-1.68vs$-1.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | — | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.06 | $-1.68 | -58.5% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-1.80 | $-1.80 | 0.0% | = MET |
Q2 2025 | May 9, 2025 | $-0.20 | $-0.23 | -15.0% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.23 | $-0.39 | -69.6% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.80 | $-0.75 | +6.3% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.75 | $-0.70 | +6.7% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.80 | $-0.69 | +13.8% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.96 | $-0.71 | +26.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.87 | $-0.87 | 0.0% | = MET |
Q3 2023 | Aug 10, 2023 | $-0.81 | $-0.78 | +3.7% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.66 | $-0.73 | -10.6% | ✗ MISS |
Q1 2023 | Mar 23, 2023 | $-0.70 | $-0.79 | -12.9% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.67 | $-0.53 | +20.9% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.66 | $-0.65 | +1.5% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.63 | $-0.56 | +11.1% | ✓ BEAT |
Q1 2022 | Mar 24, 2022 | $-0.61 | $-0.37 | +39.3% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.50 | $-0.42 | +16.0% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.37 | $-0.38 | -2.7% | ✗ MISS |
Latest News
Athira Pharma shares are trading higher after the company announced it has entered into an agreement to acquire the rights for the development and commercialization of lasofoxifene.
📈 PositiveBenzinga•Dec 18, 2025, 02:15 PM
Market-Moving News for December 18th
➖ NeutralBenzinga•Dec 18, 2025, 12:19 PM•Also: ,
Athira Pharma To Acquire Rights For Development And Commercialization Of Lasofoxifene, A Clinical Asset In Potentially Registrational Phase 3 Trial
📈 PositiveBenzinga•Dec 18, 2025, 12:05 PM
Athira Pharma Q3 EPS $(1.68) Misses $(1.20) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 09:32 PM
Athira Pharma Has Been Granted A U.S. Patent "Methods of treating neurodegenerative disease (including dementia, Alzheimer's disease, and Parkinson's disease) with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues". https://t.co/NSHLVnfwcm.
📈 PositiveBenzinga•Sep 23, 2025, 08:00 PM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Sep 18, 2025, 12:55 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Sep 17, 2025, 11:50 PM
Athira Pharma To Implement 10-For-1 Reverse Stock Split Following Shareholder Approval At May 2025 Annual Meeting
➖ NeutralBenzinga•Sep 11, 2025, 01:03 PM
Frequently Asked Questions about ATHA
What is ATHA's current stock price?
Athira Pharma, Inc. (ATHA) is currently trading at $6.97 per share. The stock has moved +3.72% today.
What is the analyst price target for ATHA?
The average analyst price target for ATHA is $4.00, based on 1 analyst.
What sector is Athira Pharma, Inc. in?
Athira Pharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ATHA's market cap?
Athira Pharma, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does ATHA pay dividends?
No, Athira Pharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADTX
Aditxt, Inc.
$1.17
Mkt Cap: $0.0B
APLM
Apollomics, Inc.
$16.73
Mkt Cap: $0.0B
CRIS
Curis, Inc.
$1.07
Mkt Cap: $0.0B
CTXR
Citius Pharmaceuticals, Inc.
$1.07
Mkt Cap: $0.0B
DARE
Daré Bioscience, Inc.
$2.09
Mkt Cap: $0.0B
FBLG
FibroBiologics, Inc. Common Stock
$0.26
Mkt Cap: $0.0B
ICU
SeaStar Medical Holding Corporation
$0.24
Mkt Cap: $0.0B
LNAI
Lunai Bioworks Inc.
$1.05
Mkt Cap: $0.0B
LPTX
Leap Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
MBRX
Moleculin Biotech, Inc.
$3.90
Mkt Cap: $0.0B
Explore stocks similar to ATHA for comparison